BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36555512)

  • 1. Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
    Ungefroren H; Künstner A; Busch H; Franzenburg S; Luley K; Viol F; Schrader J; Konukiewitz B; Wellner UF; Meyhöfer SM; Keck T; Marquardt JU; Lehnert H
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling.
    Leu FP; Nandi M; Niu C
    Mol Cancer Res; 2008 Jun; 6(6):1029-42. PubMed ID: 18567806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.
    Luley KB; Biedermann SB; Künstner A; Busch H; Franzenburg S; Schrader J; Grabowski P; Wellner UF; Keck T; Brabant G; Schmid SM; Lehnert H; Ungefroren H
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
    Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
    Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
    O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
    Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β1/Smad2/3 signaling pathway modulates octreotide antisecretory and antiproliferative effects in pituitary somatotroph tumor cells.
    Picech F; Sosa LD; Perez PA; Cecenarro L; Oms SR; Coca HA; De Battista JC; Gutiérrez S; Mukdsi JH; Torres AI; Petiti JP
    J Cell Physiol; 2021 Oct; 236(10):6974-6987. PubMed ID: 33682941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of neuroendocrine tumours to somatostatin analogs.
    Angelousi A; Koumarianou A; Chatzellis E; Kaltsas G
    Expert Rev Endocrinol Metab; 2023 Jan; 18(1):33-52. PubMed ID: 36651768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model.
    Benten D; Behrang Y; Unrau L; Weissmann V; Wolters-Eisfeld G; Burdak-Rothkamm S; Stahl FR; Anlauf M; Grabowski P; Möbs M; Dieckhoff J; Sipos B; Fahl M; Eggers C; Perez D; Bockhorn M; Izbicki JR; Lohse AW; Schrader J
    Mol Cancer Res; 2018 Mar; 16(3):496-507. PubMed ID: 29330294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.